Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

The impact of alendronate on bone mineral density of osteoporotic patients.

Authors:
Hamidreza Aghaei-Meybodi Negin Rashidi Mahdi Montazeri Abbasali Keshtkar Patricia Khashayar

Acta Med Iran 2013 ;51(12):855-60

Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

The present study assessed the real life therapeutic effects of weekly doses of alendronate in treating a group of osteoporotic patients in Iran. The present historical cohort was conducted on patients who had undergone two or more bone mineral densitometry within an interval of 1.5-2 years in Shariati Hospital bone mineral density department between 2002 and 2010.patients were asked by phone about consumption of alendronate. The mean increase in the BMD values at different sites was calculated. There was a significant increase in the body mass index (BMI) values of both the individuals taking alendronate and the control group (P<0.001). Taking the weekly dosage of the drug was associated with a 7.67% increase in the BMD values at the femoral neck, 8.68% at the total hip, and 3.17% at the lumbar spine. Moreover, our results showed a significant difference between the height decline in the two groups (alendronate taking: 0.7±2.4 vs. control: -0.7±2.6, P<0.001). Comparing the results of the present study with that of previous ones revealed the drug is beneficial in improving bone mineral density in Iranians; as well alendronate is more effective in Iranian postmenopausal women when compared with the Americans.

Download full-text PDF

Source
September 2014

Publication Analysis

Top Keywords

bone mineral
12
osteoporotic patients
8
mineral density
8
shariati hospital
4
years shariati
4
hospital bone
4
density department
4
2010patients asked
4
2002 2010patients
4
department 2002
4
interval 15-2
4
conducted patients
4
cohort conducted
4
historical cohort
4
patients undergone
4
undergone bone
4
asked phone
4
densitometry interval
4
15-2 years
4
alendronate increase
4

Similar Publications

Association between self-rated health and the risk of hip fracture and mortality in a cohort of older women during a 10-year follow-up.

Authors:
Elin Uzunel Hans Lundin Per Wändell Helena Salminen

PLoS One 2021 5;16(3):e0247924. Epub 2021 Mar 5.

Department of Neurobiology, Care Sciences and Society, Division of Family Medicine and Primary Care, Karolinska Institutet, Huddinge, Sweden.

Fragility fracture of the hip is associated with reduced functional status and mortality. Poor self-rated health (SRH) might be such an indicator. Our aim was to study if SRH was associated with hip fractures and all-cause mortality within the next 10 years in community-dwelling older women. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Safety and Efficacy of Oral Human Parathyroid Hormone (1-34) in Hypoparathyroidism: An Open-Label Study.

Authors:
Sofia Ish-Shalom Yoseph Caraco Nariman Saba Khazen Michal Gershinsky Auryan Szalat Phillip Schwartz Ehud Arbit Hillel Galitzer Jonathan Cy Tang Gregory Burshtein Ariel Rothner Arthur Raskin Miriam Blum William D Fraser

J Bone Miner Res 2021 Mar 5. Epub 2021 Mar 5.

Bioanalytical Facility, Biomedical Research Centre, Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK.

The standard treatment of primary hypoparathyroidism (hypoPT) with oral calcium supplementation and calcitriol (or an analog), intended to control hypocalcemia and hyperphosphatemia and avoid hypercalciuria, remains challenging for both patients and clinicians. In 2015, human parathyroid hormone (hPTH) (1-84) administered as a daily subcutaneous injection was approved as an adjunctive treatment in patients who cannot be well controlled on the standard treatments alone. This open-label study aimed to assess the safety and efficacy of an oral hPTH(1-34) formulation as an adjunct to standard treatment in adult subjects with hypoparathyroidism. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Anorexia Nervosa and Osteoporosis.

Authors:
Chermaine Hung Marcus Muñoz Amal Shibli-Rahhal

Calcif Tissue Int 2021 Mar 5. Epub 2021 Mar 5.

Division of Endocrinology, Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.

Patients with anorexia nervosa (AN) often experience low bone mineral density (BMD) and increased fracture risk, with low body weight and decreased gonadal function being the strongest predictors of the observed bone mineral deficit and fractures. Other metabolic disturbances have also been linked to bone loss in this group of patients, including growth hormone resistance, low insulin-like growth factor-1 (IGF-1) concentrations, low leptin concentrations, and hypercortisolemia. However, these correlations lack definitive evidence of causality. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Comparison of bone mineral density and bone mineral content in university athletes from different sports.

Authors:
Mikael S Moraes Priscila Custódio Martins Francisco E Ferreira Diego A Silva

J Sports Med Phys Fitness 2021 Mar 5. Epub 2021 Mar 5.

Federal University of Santa Catarina, Research Center in Kinanthropometry and Human Performance, Florianópolis, Brazil.

Introduction: Bone parameters are influenced by multiple factors. However, when comparing sports, few studies have considered the simultaneous interference of these factors in bone parameters.

Objective: To compare bone mineral density (BMD) and bone mineral content (BMC) between university athletes from different sports, according to sex. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Synergistic effects of magnesium ions and simvastatin on attenuation of high-fat diet-induced bone loss.

Authors:
Bingyang Dai Xu Li Jiankun Xu Yuwei Zhu Le Huang Wenxue Tong Hao Yao Dick Ho-Kiu Chow Ling Qin

Bioact Mater 2021 Aug 3;6(8):2511-2522. Epub 2021 Feb 3.

Musculoskeletal Research Laboratory of Department of Orthopedics & Traumatology and Innovative Orthopaedic Biomaterial & Drug Translational Research Laboratory, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.

Introduction: Magnesium (Mg) has a prophylactic potential against the onset of hyperlipidemia. Similar to statin, Mg is recommended as lipid-lowering medication for hypercholesterolemia and concomitantly exhibits an association with increased bone mass. The combination of statin with Mg ions (Mg) may be able to alleviate the high-fat diet (HFD)-induced bone loss and reduce the side-effects of statin. Read More

View Article and Full-Text PDF
August 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap